CCI Photonics
Spin-out from Lancaster University (est. June 2023) developing a portable point-of-care diagnostic platform to rapidly identify pathogens and antimicrobial resistance (AMR). Activities include device prototyping, biological spectral database curation, AI model development, laboratory validation, and partnerships with academic and clinical institutions to progress toward clinical adoption and market approval.
Industries
Nr. of Employees
small (1-50)
CCI Photonics
Research and Enterprise Services, Lancaster University, Bailrigg, Lancaster, LA1 4YT
Products
Portable point-of-care diagnostic device (β-prototype) for rapid AMR detection
A beta prototype portable diagnostic instrument that uses spectral data and AI models to detect pathogens and antimicrobial resistance from in-vitro and biofluid samples, aiming for rapid results.
Portable point-of-care diagnostic device (β-prototype) for rapid AMR detection
A beta prototype portable diagnostic instrument that uses spectral data and AI models to detect pathogens and antimicrobial resistance from in-vitro and biofluid samples, aiming for rapid results.
Services
Laboratory-based validation and feasibility testing of diagnostic prototypes in collaboration with research partners.
Partnerships with universities and clinical research bodies to support development, testing, and validation of diagnostics.
Laboratory-based validation and feasibility testing of diagnostic prototypes in collaboration with research partners.
Partnerships with universities and clinical research bodies to support development, testing, and validation of diagnostics.
Expertise Areas
- Point-of-care diagnostics
- Antimicrobial resistance detection
- Spectral data analytics for biological samples
- AI-driven diagnostic model development
Key Technologies
- Spectral analysis for biological samples
- Biological spectral databases
- Machine learning / AI for diagnostics
- Portable point-of-care hardware
News & Updates
Received early-stage investment (reported £200k) from the PraeSeed programme delivered by Praetura Ventures and funded through NPIF II to support prototype development and investor readiness.
Received grant funding from UK Research and Innovation to support prototype feasibility studies and validation work.
Received early-stage investment (reported £200k) from the PraeSeed programme delivered by Praetura Ventures and funded through NPIF II to support prototype development and investor readiness.
Received grant funding from UK Research and Innovation to support prototype feasibility studies and validation work.